# Null Hipothesis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/null-hipothesis

- Industry: Healthcare IT
- Headquarters: Shanghai, China
- Website: www.nullht.com
- Total disclosed funding: $14M
- Latest round: Series A (Oct 30, 2025)
- Investors on record: 4

## About

Based in Shanghai, China, Null Hipothesis is a SaaS provider specializing in intelligent medical information solutions, designed to meet the needs of healthcare professionals and pharmaceutical companies.Founded in 2019 and headquartered in Shanghai, China, Null Hipothesis focuses on developing SaaS products for the healthcare sector. The company successfully completed its SERIES A funding round in 2020 and recently secured CNY 100 million in SERIES A funding on October 30, 2025, from various investors including Guofang Fund Management and Lotus Lake Capital. This funding will bolster their initiatives in medical information technology and enhance their service offerings. The firm has been involved in 1 deal to date.Shanghai Null Hypothesis Information Technology Co., Ltd. offers a comprehensive suite of SaaS products under the KnowS series, designed to facilitate the large-scale intelligent output of professional medical information content. These products serve healthcare professionals and pharmaceutical companies, featuring tools like an automated drug comparison analysis tool, an AI-driven medical evidence retrieval engine, and intelligent medical information tracking systems. The primary market focus is in the pharmaceutical and healthcare sectors in China, with plans for gradual expansion into other regions.The revenue structure of Shanghai Null Hypothesis Information Technology Co., Ltd. is mainly based on subscription models for its KnowS products. Clients, typically healthcare institutions and pharmaceutical companies, pay for annual subscriptions or licensing fees for access to these specialized tools. While specific pricing details are confidential, the products are designed to deliver substantial value by leveraging data science and medical expertise. The company raised CNY 100 million during its SERIES A financing round, underpinning its growth and development goals.Looking ahead, Null Hipothesis aims to refine and deploy scenario-based AI medical intelligent agents. The recent funding from the SERIES A round will primarily support the establishment of an academic communication bridge connecting pharmaceutical companies and healthcare professionals. The company is also targeting expansion beyond China into new geographical markets, with specific plans to broaden its reach and impact by 2026.

## Funding rounds

- Series A, Oct 30, 2025, $14M — Oriza Holdings, Lotus Lake Capital, Shanghai Growth Investment, Shanghai Zheyu Investment

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series A
- Shanghai Growth Investment (https://capitalatlas.ai/funds/shanghai-growth-investment) — Series A
- Shanghai Zheyu Investment — Series A